No Data
No Data
BeiGene Says New Phase 3 Brukinsa Data Show 'Promising' Efficacy in Leukemia, Lymphoma
BeiGene (BGNE) said Friday that preliminary data from a phase 3 study of Brukinsa in combination with venetoclax to treat patients with chronic lymphocytic leukemia and/or small lymphocytic lymphoma s
Express News | Beigene: Safety Profile Was Consistent With Results of Prior Brukinsa Studies
Express News | Beigene: Preliminary Data Suggest Promising Efficacy and Tolerability
Express News | Beigene: To Present New Data From Sequoia Study Evaluating Brukinsa® Plus Venetoclax in High-Risk First-Line Cll/Sll
BeiGene to Present New Data From SEQUOIA Study Evaluating BRUKINSA Plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
Arm D of SEQUOIA study evaluated treatment-naïve patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma with del(17p) and/or TP53 mutation Preliminary data suggest promising efficacy and
BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region
DUBAI, United Arab Emirates--(BUSINESS WIRE)--$BGNE #BeiGene--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, and NewBridge Pharmaceuticals have jointly decided to conclud